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Objectives. To assess the induced sputum substance P (ISSP) levels in children having diﬃcult-to-treat asthma (DA) with and
without gastroesophageal reﬂux (GER). We aimed also to evaluate the association of GER with childhood DA, relationship of
GER severity with childhood asthma control test (C-ACT), FEV1, peak expiratory ﬂow (PEF) variability, and ISSP. Finally, we
tried to evaluate esomeprazole treatment eﬀect on C-ACT and FEV1 in children with DA. Methods. Spirometry, C-ACT, upper
gastrointestinal endoscopy, and ISSP measurement were done for children with DA compared to healthy controls. Results. ISSP
was high in DA with higher levels in the group having associated GER. In the latter group, ISSP and C-ACT improved signiﬁcantly
after esomeprazole treatment while FEV1 and PEF variability did not improve. Reﬂux severity was positively correlated with ISSP
and negatively correlated with FEV1. Conclusions. GER was found in 49% of our patients with childhood DA. Very high ISSP levels
in children with DA may be used as a marker for presence of GERD. Esomeprazole therapy improved asthma symptoms but did
not improve lung function.
1.Introduction
Asthma is a common chronic complex inﬂammatory airway
disordercharacterizedbyvariabledegreesofrecurringsymp-
toms of airﬂow obstruction and bronchial hyperresponsive-
ness[1].Althoughthemajorityofasthmapatientscanobtain
the targeted level of control, some patients will not achieve
control even with the best therapy [2]. Patients who do not
reach an acceptable level of control with the use of reliever
medication plus two or more controllers can be considered
to have diﬃcult-to-treat asthma [3].
The association between asthma and gastrooesophageal
reﬂux (GER) has been debated for decades when Sir William
Osler ﬁrst observed the association between worsening asth-
ma and distended stomach in 1892 [4] .T h ep r e v a l e n c eo f
symptoms of GER among individuals with asthma is sub-
stantially higher than in normal population and similarly the
prevalence of asthma in individuals with GER is also higher
t h a ni nc o n t r o l s[ 5].
Gastroesophageal reﬂux (GER) may cause chronic respi-
ratory disease by vagal response and tracheal aspiration of
gastric contents [6]. Aspiration of gastric contents changes
pulmonary resistance and causes reactive airway obstruction
[7]. Gastrooesophageal reﬂux may contribute to airway in-
ﬂammatory events, possibly by sensory nerve stimulation
and thesubsequentreleaseof tachykinins into the airway [8].
ThetachykininsassubstanceP(SP)andneurokininAare
the neuropeptides most often associated with axonal reﬂexes
and are potent mediators of cough, bronchospasm, micro-
ascular leakage, and mucus secretion [9]. Asthmatic patients2 International Journal of Pediatrics
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Figure 1: The study design, groups, and subgroups.
have reduced lower esophageal sphincter pressure and take
longer to perform esophageal clearance [10]. In addition,
asthmamedicationssuchasbetaagonistsandtheophyllinre-
duceloweresophagealsphincterpressureandincreasegastric
acid secretion [6, 11].
The prevalence of GERD in children with asthma has
been shown to be between 19.3% and 80% in diﬀerent stud-
ies [12]. The diagnosis of GERD is not easy in patients with
diﬃcult-to-treat asthma as GER may present solely with re-
spiratory manifestations (occult GER). In children, GER can
present with bronchiolitis, pneumonitis, and even failure to
thrive. Other common GER respiratory manifestations are
chronic coughing, asthma, laryngeal spasm, apnea, stridor,
pulmonary dysplasia, and cyanotic crises. Nocturnal wheez-
ing or coughing, with inadequate response to medical treat
ment for asthma, negative family history of atopy and early
onset of bronchial hyperreactivity can distinguish these pa-
tients [13]. So, there is a need for a simple test to predict
the presence of GERD among children with diﬃcult-to-treat
asthma.
We hypothesized that measurement of induced sputum
levels of substance P (SP) can be a helpful tool to anticipate
presence of GERD in children with diﬃcult-to-treat asth-
ma. So, we aimed to assess the induced sputum substance
P (ISSP) levels in children having diﬃcult-to-treat asthma
(DA) with and without gastro esophageal reﬂux (GER). We
aimedalsotodetecttheassociationofGERwiththediﬃcult-
to-treat asthma in children, as well as to determine the rela-
tionship between severity of GER as assessed by upper GIT
endoscopy and the childhood asthma control test (C-ACT),
forced expiratory volume in the 1st second (FEV1), peak
expiratory ﬂow (PEF) variability and induced sputum levels
of SP. Also this study aimed to determine the eﬀect of
antireﬂux therapy with esomeprazole as proton pump in-
hibitors (PPI) on the C-ACT, FEV1, PEF variability, and
induced sputum levels of SP in children having diﬃcult-to-
treat asthma with GERD.
2. Patients andMethods
Figure 1 showed the study design, where 59 children between
5 and 11 years of age (diagnosed with diﬃcult-to-treat bron-
chial asthma) and attending the Asthma Clinic of Pediatric
and Pulmonology Department at International Hospital of
Bahrain, a tertiary care hospital, Kingdom of Bahrain. Pa-
tients were identiﬁed from the clinic database according to
the guidelines of the National Asthma Education and Pre-
vention Program [1] from January 2009 to January 2011.
Fifty healthy children of matched age and sex were studied
as a control group.
2.1. Deﬁning the Cases. Asthma was deﬁned on the basis
of symptoms together with documented reversible airﬂow
obstruction (increase FEV1 by more than 12% after inhaled
short-acting β2-agonist) and PEF variability ≥20% [14].
Asthmatic children fulﬁlled the criteria for diﬃcult-to-treat
asthma, that is, all had persistent refractory symptoms, were
receiving maintenance therapy of inhaled steroids (≥400μg
beclomethasone dipropionate or equivalent per day) and
long-acting β2-agonist and had received at least one course
of systemic steroids in the preceding 12 months [15].
Patients with diﬃcult to treat asthma were further
subdivided into 2 subgroups according to the presence of
s i g n so fG E R Do nu p p e rG I Te n d o s c o p y .
(i) Children with diﬃcult-to-treat asthma and GERD.
(ii) Children with diﬃcult-to-treat asthma without
GERD.
All asthmatic patients were managed according to GINA
(Global Initiative for Asthma) guideline 2008 with treatment
being stepped up and down as appropriate.
2.2.TheFollowingWasDoneforAllSubjects. Detailedhistory
taking and thorough clinical examination with special stressInternational Journal of Pediatrics 3
on GIT symptoms suggestive of reﬂux including heart burn,
acid regurgitation and food regurgitation. In asthmatic
patients Childhood Asthma Control Test (C-ACT) was done.
It is a seven-item child- and caregiver-completed tool with a
scoring range of 0–27; higher scores indicate better control.
A score of 19 or less indicates that the asthma may not be
well controlled. The C-ACT is intended for use in children
up to the age of 12 years [16]. Chest X ray posteroanterior
and lateral views were done to exclude other pulmonary dis-
eases (e.g., TB, bronchiectasis, cystic ﬁbrosis, congenital
anomalies, etc.). Abdominal ultrasonography was done to
exclude organomegaly. Spirometry using calibrated comput-
erized machine (Jaeger MasterScreen-Body/Diﬀusion, Jae-
ger, Germany) was done for all cases with special stress on
FEV1, and peak expiratory ﬂow (PEF) variability. The PEF
variability was calculated as the percentile ratio of the dif-
ference between maximum and minimum PEF to the mean
daily PEF over a period of one week, that is, (maximum PEF
−minimumPEF)/(meanofallPEFsover1week) ×100[17].
2.2.1. Upper Gastrointestinal Endoscopies Were Done. by
using an Olympus GIF-P140 Pediatric Video Gastroscope
with 8.5mm diameter, and 2.2mm channel. The endoscopic
ﬁndings of esophagitis were classiﬁed according to Los
Angeles classiﬁcation to the following grading: Grade A
(score 1): 1 or more mucosal breaks each ≤5mm in length.
G r a d eB( s c o r e2 ) :a tl e a s to n em u c o s a lb r e a k>5mmlong,
but not continuous between the tops of adjacent mucosal
folds. Grade C (score 3): at least one mucosal break that
is continuous between the tops of adjacent mucosal folds.
Grade D (score 4): mucosal break that involve at least three-
fourth of the luminal circumferences. Patient took score 0 if
there were no features of reﬂux [16]. Upper gastrointestinal
endoscopy was not done in the control group except in 2
cases, because an informed consent could not be obtained
from the families to do such invasive technique. The two
cases that had been examined with endoscopy had a strong
clinical history of GERD.
2.2.2. Induced-Sputum Production. Sputum was collected
either spontaneously or induced with hypertonic saline neb-
ulization from all subjects. Prior to sputum induction,
children inhaled 200μg of salbutamol to minimize broncho-
constriction during the induction procedure. Sputum was
induced by inhalation of 3% hypertonic saline solution for
5min using an ultrasonic nebulizer, and the subjects were
encouraged to cough and expectorate sputum into sterile
containers. FEV1 was measured after nebulization. Nebuli-
zation was stopped if a fall in FEV1 of >20% compared to
baseline values occurred or if troublesome symptoms ap-
peared [18].
2.2.3. Sputum Substance P (SP) Measurement. SP was meas-
ured using a commercially available enzyme linked immun-
osorbent assay (ELISA; R and D Systems, Oxon, UK). It has
nosigniﬁcantcross-reactivitywithneurokininA,neurokinin
B, or neuropeptide K. The limit of detection of this assay is
0.06ng/mL.
2.2.4. The Group of Children Who Had Diﬃcult-to-Treat
Asthma with Reﬂux. Further received medical treatment for
reﬂux in the form of proton pumps inhibitors (PPI) for 12
weeks (esomeprazole capsule 20mg/day) beside the usual
antiasthma medications as mentioned before. The group of
children who had diﬃcult-to-treat asthma without reﬂux re-
ceived placebo identical appearing capsules containing lac-
tose(placebocapsule/day)for12weeksbesidetheusualanti-
asthma medications as mentioned before.
All children proved to have GERD either asthmatic or
the control group were screened forHelicobacter Pylori infec-
tion and the positive cases received metronidazole and clar-
ithromycin beside the esomeprazole (triple therapy).
So, all asthmatic patients with GERD received PPI and
none of them received placebo because it is unethical to give
placebototheminsteadofpropertreatmentandalsobecause
ifwedividetheminto2subgroups,thenumberofpatientsin
each of them will be low and the power of work would be re-
duced.
On the other hand, we gave placebo to asthmatic patients
withoutGERDtoruleouttheplaceboeﬀectonimprovement
in the other group and to exclude the eﬀect of better patient
adherence to prescribed medications and better follow up by
regular attendance to the clinic.
2.3. After 12 Weeks the Following Evaluations Were Repeated.
Upper GIT endoscopy; for the group who received antireﬂux
treatment, C-ACT, pulmonary function testing, and sub-
stance P measurement in induced sputum for both groups
of patients with diﬃcult-to-treat asthma.
Parents of all patients and control subjects signed a
written informed consent before enrolment into the study.
The local Institutional Research Ethics Committee approved
the study protocol.
2.4. Statistical Analysis. The power level of the number of
cases in the study was more than 80%. Statistical analysis
was performed with Statistical Package for Social Sciences
(SPSS), version 16.0 (Chicago, IL, USA). Data are presented
as mean (±SD) values. Comparison between the studied
groups was performed with Students t-test, with P<0.05
considered statistically signiﬁcant. Wilcoxon’s signed rank
test was used to assess the normality of distributions of the
data. The Bonferroni correction/adjustment procedure was
done to avoid “signiﬁcance” due to chance only, in multiple
comparisonwithmanyparameters.Correlationbetweenvar-
iables was evaluated using Pearson’s correlation coeﬃcient.
3. Results
The study design and the demographic data of patients and
the control subjects as well as their clinical data are shown in
Figure 1 and Table 1. There was no signiﬁcant diﬀerence in
the age and sex between the patients group and the control.
However, the body mass index (BMI) was signiﬁcantly
lower in the patient group than the control children. Table 1
also showed that the blood eosinophils, PEF variability,
and sputum SP were signiﬁcantly higher in children with4 International Journal of Pediatrics
Table 1: Demographic data, associated comorbidities, FEV1, PEF variability, and induced sputum SP in patients and control group.
Asthmatic (n = 59) Control (n = 50) tP
Age 8.2 ±1.85 8.0 ±1.70 . 4 >0.05
BMI 18.4 ±1.42 0 .6 ±2.36 . 9 <0.001∗
M/F 1.1:1 1.2:1 0.2 >0.05
Age at diagnosis 4.7 ±1.5— — —
Associated nasal allergy 35 (59%) 4 (8%)
Atopic dermatitis 24 (41%) 3 (6%)
Immediate family history of asthma 40 (68%) 2 (4%)
Smoking parents 13 (22.03%) 12 (24%)
Long-acting β-agonists 59 (100%)
High-dose inhaled corticosteroids 59 (100%)
leukotriene modiﬁers 41 (69.49%)
Theophylline 35 (59.32%)
Blood eosinophils (%) 5.9 ±2.12 .02 ±0.9 12.5 <0.001∗
FEV1 (% of predicted) 58.4 ±6.98 99.4 ±5.8 30.6 <0.001∗
PEF variability (%) 40.2 ±4.91 3 .2 ±2.2 34.3 <0.001∗
Sputum SP (pg/mL) 1320.9 ±288.9 584.0 ±43.9 17.6 <0.001∗
BMI: body mass index; EFV1: forced expiratory volume in the 1st second; PEF variability: peak expiratory ﬂow variability; sputum SP: sputum levels of
substance P.
∗P<0.05 is signiﬁcant.
Table 2: Demographic data, C-ACT, FEV1, PEF variability, and induced sputum SP in patient group with diﬃcult-to-treat asthma with and
without GERD.
Diﬃcult-to-treat asthma with GERD
N = 29
Diﬃcult-to-treat asthma without
GERD N = 30 tP
Age 7.97 ±1.56 7.96 ±1.80 . 0 3 >0.05
SexM:F 15:14 16:14
BMI 20.5 ±2.52 1 .0 ±2.05 0.88 >0.05
Age at diagnosis 4.7 ±1.64 .9 ±1.40 . 4 >0.05
C-ACT 12.7 ±3.91 2 .8 ±3.20 . 1 2 >0.05
FEV1 (% of predicted) 57.1 ±7.96 0 .1 ±4.71 . 8 >0.05
PEF variability (%) 40.7 ±5.63 9 .4 ±3.61 . 2 >0.05
SP (pg/mL) 1503 ±84 1004 ±258 9.2 <0.001∗
BMI: body mass index; C-ACT: childhood asthma control test; EFV1: forced expiratory volume in 1 second; PEF variability: peak expiratory ﬂow variability;
sputum SP: sputum levels of substance P.
∗Signiﬁcant.
diﬃcult-to-treat asthma than the control children, but FEV1
(% of predicted) and C-ACT was signiﬁcantly lower in
children with diﬃcult-to-treat asthma than the control.
Table 2 showed the demographic and clinical data of
the children with both diﬃcult-to-treat asthma and GERD
(29 children) and those children who have diﬃcult-to-treat
asthma with no GERD (30 children). There was no signiﬁ-
cantdiﬀerenceinage,sex,BMI,ageatdiagnosis,C-ACT,PEF
variability, and FEV1 (% of predicted) between the two sub-
groups. However, the sputum SP was signiﬁcantly higher in
children with diﬃcult-to-treat asthma and GERD than in
those who have diﬃcult-to-treat asthma without GERD.
Table 3 showed a signiﬁcant positive correlation between
reﬂux severity score and induced sputum SP. There were sig-
niﬁcant negative correlations between FEV1 and both reﬂux
severityscoreandinducedsputumSP.C-ACThadsigniﬁcant
negative correlations with both reﬂux severity score and
induced sputum SP.
Table 4 showed the eﬀect of 12 weeks treatment with
esomeprazole on children with diﬃcult-to-treat asthma and
GERD.ItshowedsigniﬁcantimprovementofC-ACTandsig-
niﬁcant reduction of sputum SP after treatment than before
treatment.However,FEV1 (%ofpredicted)andPEFvariabil-
ity showed no signiﬁcant changes. This table also showed no
signiﬁcant eﬀect of the placebo treatment on children with
diﬃcult-to-treat asthma without GERD.
As mentioned in the methodology section, management
of asthma was done according to GINA guideline 2008 with
treatment stepped up and down as required. Among the
59 children patients with diﬃcult-to-treat asthma, sevenInternational Journal of Pediatrics 5
Table 3: Correlations between studied parameters in asthmatic
patients with reﬂux in children with diﬃcult-to-treat asthma.
Correlation between rP
Reﬂux severity score and C-ACT −0.74 <0.001∗
Reﬂux severity score and FEV1 −0.64 <0.001∗
Reﬂux severity score and PEFV 0.65 <0.001∗
Reﬂux severity score and induced
sputum SP 0.80 <0.001∗
Induced sputum SP and ACT −0.67 <0.001∗
Induced sputum SP and FEV1 −0.49 <0.001∗
Induced sputum SP and PEFV 0.45 <0.001∗
C-ACT: childhood asthma control test; EFV1: forced expiratory volume in 1
second;PEFvariability:peakexpiratoryﬂowvariability;sputumSP:sputum
levels of substance P.
∗Signiﬁcant.
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Figure 2: Eﬀect of 12 weeks of treatment with esomeprazole on
reﬂux grade in patient group with diﬃcult-to-treat asthma and
GERD.
patients required stepping up of asthma therapy (three with
GERDandfourwithoutGERD)whileeightpatientsrequired
stepping down (four with GERD and four without GERD).
Figure 2 showed the endoscopic reﬂux scores in children
with diﬃcult-to-treat asthma and GERD. Eight patients
(27.59%) had grade A, six patients (20.69%) had grade B,
seven patients (24.13%) had grade C, and eight patients
(27.59%) had grade D. After 12 weeks of esomeprazole
treatment, six patients (20.69%) had grade A, ﬁve patients
(17.24%) had grade B, ﬁve patients (17.24%) had grade
C, three patients (10.35%) had grade D, and ten patients
(34.48%) showed no endoscopic signs of reﬂux (Figure 2).
Twenty-four children (82.7%) had improvement in reﬂux
score after PPI treatment. Only ﬁve children (17.3%) showed
no improvement in endoscopic reﬂux score after treatment,
three of them were grade D and remained the same after
treatment and two of them were grade C and remained the
same after treatment. Two cases among the nonresponders
were proved to have Helicobacter pylori infection. Also the
two control children who had GERD had concomitant
infection with Helicobacter pylori.
4. Discussion
Because of the high incidence of gastro-esophageal reﬂux
(GERD) in patients with asthma [12], the complex relation-
ship between them, and ﬁnally the diﬃculty of diagnosing
GERD among asthmatic patients we designed this study.
GERD may simply represent just an associated unrelated
ﬁnding with asthma, it may worsen the severity of asthma, or
could be a consequence of asthma itself [19]. According to
the best of the authors’ knowledge, this is the ﬁrst work that
use induced sputum substance P in assessment of gastro-
esophageal reﬂux (GERD) in children with diﬃcult-to-treat
asthma.
The wide diﬀerence in GERD prevalence from one study
to another (between 19.3% and 80% in diﬀerent studies)
depends on the method of reporting of GERD (pH moni-
toring, scintigraphy, endoscopy, and radiologic options) and
on the patients’ criteria of the studied groups [12].
One of the points that we were concerned about in
the current study was the association of GERD in a rela-
tively homogenous group of children with diﬃcult-to-treat
asthma. Children with diﬃcult-to-treat asthma and GERD
made up to 49% of the studied patient group. Kwiecien et al.
2011 found that the intensity of GER was signiﬁcantly
correlated with severity and the diﬃculty-to-control asthma
attacks in asthmatic children [20]. Their ﬁnding can explain
the high prevalence of GERD in the current study. In the
current study, there was a positive correlation between
endoscopic reﬂux severity score (as an indicative of GERD
severity) and the asthma severity (as indicated by lower C-
ACT, FEV1, and the higher PEF variability and sputum SP).
Withincreasing severityof asthma,thereisa need toincrease
the dose and the number of antiasthma medication. In the
current study, all the asthmatic children were receiving long-
acting Beta-2 agonists and high-dose inhaled corticosteroids.
Asthma medications such as beta agonists and theophyllin
reduce lower esophageal sphincter tone and increase gastric
acid secretion [7]. Systemic steroids have been shown to
increase GERD in asthma patients [11]. The asthma itself
may predispose to the occurrence of GERD by increasing
pressure gradient between the thorax and the abdomen
with reduction of lower esophageal sphincter pressure and
lengthening of the time needed to perform esophageal
clearance [21]. On the other hand, the reﬂux is an important
asthma trigger. The potential mechanisms include a vagally
mediated esophageal tracheobronchial cough reﬂex, a local
axonal reﬂex, heightened bronchial reactivity, and micro- or
macroaspiration into tracheobronchial tree [10, 22].
Being a common ﬁnding in children with diﬃcult-to-
treat asthma, presence of GERD must be ruled out in such
cases. In the current study, there was a signiﬁcant increase of
sputum SP in children with diﬃcult-to-treat asthma and
GERDthanbothcontrolchildrenandchildrenwithdiﬃcult-
to-treat asthma without GERD. In addition, the level of
sputum SP signiﬁcantly decreased in children with diﬃcult-
to-treat asthma and GERD after 12 weeks of treatment
with the proton pump inhibitor (PPI) esomeprazole. This
agreed with the work of Patterson et al. 2007, who found
that sputum SP and neurokinin A (NKA) were signiﬁcantly6 International Journal of Pediatrics
Table 4:ACT,FEV1,PEFvariability,andinducedsputumSPinchildrenwithdiﬃcult-to-treatasthmawithGERDtreatedwithesomeprazole
and children with diﬃcult-to-treat asthma without GERD treated with placebo before and after treatment.
Before treatment After treatment tP
Children with diﬃcult-to-treat asthma and GERD (n 29)
C-ACT 12.7 ±3.99 15.03 ±4.4 11.6 <0.001∗
FEV1 (% of predicted) 57.1 ±7.95 7 .6 ±7.61 . 2 >0.05
PEF variability (%) 40.7 ±5.54 0 .3 ±5.21 . 6 >0.05
SP (pg/mL) 1502 ±83.6 1198 ±223.59 . 4 <0.001∗
Children with diﬃcult-to-treat asthma without GERD (n 30)
C-ACT 12.9 ±3.31 2 .7 ±2.91 . 9 7 >0.05
FEV1 (% of predicted) 60.2 ±4.66 0 .4 ±4.50 . 5 9 >0.05
PEF variability (%) 39.3 ±3.63 8 .9 ±3.21 . 6 >0.05
SP (pg/mL) 1.68.6 ±65.3 1067.6 ±67.10 . 2 5 >0.05
BMI: body mass index; C-ACT: childhood asthma control test; EFV1: forced expiratory volume in 1 second; PEF variability: peak expiratory ﬂow variability;
sputum SP: sputum levels of substance P.
∗Signiﬁcant.
higherinadultpatientswithreﬂuxthanthosewithoutreﬂux.
Also they found signiﬁcantly higher levels of sputum SP
and NKA in adult asthmatic patients with reﬂux than in
adult asthmatic patients without reﬂux. They suggested that
acid in the esophagus caused sensory nerve stimulation and
release of tachykinins into the airways [8]. Liu et al. 2005,
also found that SP concentration was high in airways of
adult GERD patients with cough [23]. Substance P is one
of the tachykinins peptides that can cause many patho-
physiological features of neurogenic inﬂammation and is
secreted from sensory airway nerves and inﬂammatory cells
after allergens exposure [9]. They are potential mediators of
asthma through their potent eﬀects on the bronchomotor
tone, airway secretion, bronchial circulation (vasodilatation
and microvascular leakage) as well as on inﬂammatory and
immune cells [24]. From the results of the current study
as well as the study of Patterson et al. and Liu et al. we
can expect presence of associated GERD in children with
diﬃcult-to-treatasthmaifthesputumSPlevelissigniﬁcantly
high. However, we did not deﬁne a cutoﬀ value of sputum SP
with the highest sensitivity to expect presence of GERD in
asthmatic children.
In the current study, childhood-asthma control test (C-
ACT) in patients with both diﬃcult asthma and GERD
showed signiﬁcant increase after 12 weeks of treatment
with esomeprazole. This agreed with a number of studies
done in asthmatics with GERD. Khoshoo and Haydel, 2007,
showed a signiﬁcant improvement in asthma symptoms
and decreased requirement for asthma medication in 25
nonatopic asthmatic children treated with acid suppressor
treatment [25]. Khoshoo et al. 2009, found that contin-
ued treatment with a proton pump inhibitor/prokinetic
combination in children with moderate-persistent asthma
and concomitant GERD had shown signiﬁcant clinical
improvement in asthma symptoms and no exacerbations
for more than 3 months [26]. Y¨ uksel et al. 2006, showed
that GERD therapy with famotidine signiﬁcantly decreased
respiratory symptoms in preschool children with asthma
[27]. Another study done by Yoshida et al. 2008, showed that
the anti-GERD treatment signiﬁcantly improved bronchial
hyperreactivityasindicatedbymethacholinechallengetestin
thirty nonatopic children with persistent asthma [28]. Other
studiesdoneinadultasthmaticsalsoagreedwiththeresultof
thecurrentstudy.Hardingetal.1996,foundthatomeprazole
improved asthma symptoms in 67% of asthmatics with
GERD after 3 months of therapy [29]. Calabrese et al. 2005
found that treatment with pantoprazole for 6 months caused
signiﬁcant improvement of asthma symptoms and FEV1 in
the adult asthmatics [30].
However,Størdaletal.2005foundthatPPItreatmentdid
not improve asthma symptoms or lung functions in children
with asthma and GERD. This dissimilarity from the result of
the current study may arise from the diﬀerence in their stud-
ied group which included children with mild or moderate
persistent asthma, and relatively well-controlled asthma on
dailyinhaledsteroids;sothatfurtherimprovementinasthma
outcome may be diﬃcult to be obtained. They also assessed
the improvement in asthma symptoms using asthma scoring
questionnaire which is diﬀerent from the C-ACT. They used
omeprazole 20mg daily while in the current study we used
esomeprazole 20mg daily [31].
Maev et al. 2003, showed that therapy of bronchial
asthma associated with GERD using omeprazole in the dose
equal to 40mg per day or esomeprazole in the dose equal to
40mg per day contributed to a reliable improvement of both
pulmonary and esophageal symptoms. However, application
of esomeprazole resulted in a faster reduction of bronchial
obstruction and gastroesophageal reﬂux [32].
In the current study, despite the signiﬁcant improvement
of C-ACT after GERD treatment with esomeprazole, there
was no signiﬁcant improvement of FEV1 and PEF variability.
This ﬁnding agreed with a number of studies done in both
children and adults with asthma and concomitant GERD.
Teichtahl et al. 1996, found no signiﬁcant diﬀerences in
FEV1, FVC, histamine bronchial responsiveness, and diurnal
variationofPEFRbetweenplaceboand4weeksof40mg/day
of omeprazole treatments in in adult patients with both
asthma and GERD [33]. The same ﬁnding was documentedInternational Journal of Pediatrics 7
by Boeree et al. 1998, who also found no beneﬁcial role
for intensive antireﬂux therapy with high-dose omeprazole
(40mg twice daily for 3 months) to improve pulmonary
symptoms and function in patients with asthma and chronic
obstructive pulmonary disease, who have severe airway
hyperresponsiveness despite maintenance treatment with
inhaled corticosteroids [34]. Although Levin et al. 1998,
found improvement of peak expiratory ﬂow rate and quality
of life in asthmatics with gastroesophageal reﬂux after daily
use of omeprazole 20mg for 8wk, the increase in FEV1
failed to reach statistical signiﬁcance [35]. Another cross-
sectional study done by Kiljander et al. 1999, showed that 8
weeks of treatment with daily omeprazole 40mg succeeded
to reduce nocturnal asthma symptoms, but failed to improve
daytime asthma outcome [36]. Lack of improvement in
lung functions in asthmatic patients with reﬂux after acid
suppression may be due to presence of nonacid reﬂux.
Weakly acidic and nonacidic reﬂux events are known to
trigger cough events in humans [37]. In addition, distension
of the oesophagus by reﬂuxate induces airway protective
reﬂexes [38].
4.1. Limitations of the Study. Esomeprazole was the only
antireﬂux therapy used during the study. It may be inade-
quate especially for treating cases with high reﬂux score. This
is clearly appearing in lack of improvement of the GERD
in 3 cases with reﬂux score of 4. Lack of prokinetic med-
ications use during the study may be an explanation for
the nonsigniﬁcant improvement in pulmonary functions
as nonacidic reﬂuxate still can trigger the airway reﬂexes.
Another limitation in the current study is lack of determi-
nation of a cutoﬀ point for sputum SP that can be more
sensitive to detect the presence of GERD in such cases.
Further studies are needed to determine the eﬀect of poly
antireﬂux therapy on the pulmonary function as well as to
determine the cutoﬀ point for sputum SP level with high
sensitivity to detect presence of GERD in asthmatic children.
Another limitation of the current study is using endoscopy
for diagnosing GERD not pH or impedance studies that may
be more sensitive as there will be some false-negative cases
with the use of endoscopy. The endoscopy used because it
was the available tool in our hospital. Finally, lack of control
subjects for presence of GERD may be considered as another
limitation.
5. Conclusion
Gastro-esophageal reﬂux (GER) was found in about 49%
of patients with childhood diﬃcult-to-treat asthma. Proper
GER therapy can improve asthma symptoms as indicated
by childhood asthma control test (C-ACT); however, it has
insigniﬁcant eﬀects on lung function as indicated by FEV1
and peak expiratory ﬂow variability. Very high level of
induced sputum substance P (SP) in children with diﬃcult-
to-treatasthmamaybeusedasanovelmarkerfordiagnosing
GER in such children.
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